Survival Rate in Lung Adenocarcinoma with Mutation of the EGFR Gene with Tyrosine Kinase Inhibitor Treatment
DOI:
https://doi.org/10.3889/oamjms.2022.9459Keywords:
Survival rate, Progression-free survival, EGFR-TKI, Lung adenocarcinomaAbstract
Background: EGFR mutation is a genetic disorder that is often observed and examined in Non-Small Cell Lung Carcinoma. EGFR mutation detection aims to predict sensitivity to EGFR-TKI and acts as first-line therapy. Targeted therapy with EGFR-TKI can increase the survival rate of patients with Non-Small Cell Lung Cancer compared to chemotherapy. This study aims to obtain data on the survival rate of patients with Non-Small Cell Lung Carcinoma who received targeted therapy at H. Adam Malik Hospital.
Methods: This study is a descriptive study with a retrospective cohort design carried out at the Oncology Polyclinic at RSUP H Adam Malik Medan for 5 years, from January 2014 to December 2018. The subjects of this study were all patients with lung cancer type adenocarcinoma who had received therapy with generation 1 or 2 EGFR TKI.
Results: 99 patients were included as subjects of this study. From the study, the most influential factors on lung cancer were gender, age, and smoking addiction. The study consisted of 60.6% male, 92.9% of the respondents aged 40 years and over, 56.5% active, and 43.4% passive smokers and 41.4% of the respondents with severe Brinkman index. The 30-month survival rate of EGFR-TKI (Gefitinib) patients treated with NSCLC Adenocarcinoma (Gefitinib) from 2014 to 2018 at H. Adam Malik Hospital Medan was 6.3% with a median survival of 7 months. The duration of progression-free survival in patients receiving Erlotinib therapy was 6.6 months (6.6 ± 2.51 months), while the length of progression-free survival for patients treated with Gefitinib was 9.1 months (9.1 ± 6.9 months). The results of statistical tests showed that there was no difference in progression-free survival rate between those who received Erlotinib and Gefitinib (P = 0.82).
Conclusion: The 30-month survival rate of lung adenocarcinoma patients treated with EGFR-TKI from 2014 to 2018 was 6.1% with a median survival of 7 months. Those who received Erlotinib therapy experienced Progression-Free Survival for 6.6 months and those who received Gefitinib experienced Progression-Free Survival for 9.1 months.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Siegel RL, Miller KD, Jemal A. Cancer statistics of American 2019. CA Cancer J Clin. 2019;69(1):7-34. https://doi.org/10.3322/caac.21551 PMid:30620402 DOI: https://doi.org/10.3322/caac.21551
Agustina TS, Wulandari L. Perbandingan Respons Terapi Gefitinib pada Pasien KPKBSK EGFR Mutasi Ekson 19 dan Ekson 21. J Respir Indo. 2017;37.
Ahmad Y, Yousif H. Treatment of epidermal growth factor receptor mutation in non-small cell lung cancer: Current role and the future perspective. J U Unexplored Med 2017;2:39-47. DOI: https://doi.org/10.20517/2572-8180.2017.03
Ambarita AN. Response Evaluation Criteria in Solid (RECIST) Pada Pasien Kanker Paru Jenis Adenokarsinoma dengan Gen EGFR Mutasi Yang Mendapat Target Terapi di RSUP Haji Adam Malik Medan. FK USU; 2019.
Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, et al. Clinically meaningful improvement in symptoms and quality life for patients with non small cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005;23(13):2946-54. https://doi.org/10.1200/JCO.2005.05.153 PMid:15699477 DOI: https://doi.org/10.1200/JCO.2005.05.153
De Luca A, Normanno N. Predictive biomarker to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small cell lung cancer. Curr Drug Targets. 2010;11(7):851-64. https://doi.org/10.2174/138945010791320773 PMid:20388064 DOI: https://doi.org/10.2174/138945010791320773
DeRouen MC, Hu L, McKinley M, Gali K, Patel M, Clarke C, et al. Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California’. PLoS One. 2018;13(5):e0197146. https://doi.org/10.1371/journal.pone.0197146 PMid:29791458 DOI: https://doi.org/10.1371/journal.pone.0197146
Fischer OM, Hart S, Gschwind A, Ulrich A. EGFR signal Transactivation in Cancer Cells. Biochem Soc Trans. 2003;31(6):1203-7. DOI: https://doi.org/10.1042/bst0311203
Soeroso NN, Zain-Hamid R, Sinaga BY, Sadewa AH, Syafiuddin T, Syahruddin E, et al. Genetic polymorphism of CYP2A6 and its relationship with nicotine metabolism in male bataknese smokers suffered from lung cancer in Indonesia. Open Access Maced J Med Sci. 2018;6(7):1199-205. https://doi.org/10.3889/oamjms.2018.259 PMid:30087722 DOI: https://doi.org/10.3889/oamjms.2018.259
Tarigan SP, Soeroso NN, Tumanggor CA, Gani S, Pradana A. Clinical profile of male patients with non-small cell lung cancer in adam malik general hospital, Medan, Indonesia. Open Access Maced J Med Sci. 2019;7(16):2612-4. https://doi.org/10.3889/oamjms.2019.404 PMid:31777616 DOI: https://doi.org/10.3889/oamjms.2019.404
Syahruddin E, Wulandari L, Muktiati NS, Rima A, Soeroso N, Ermayanti S, et al. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed indonesian lung cancer patients. Lung Cancer. 2018;9:25-34. https://doi.org/10.2147/LCTT.S154116 PMid:29615847 DOI: https://doi.org/10.2147/LCTT.S154116
He B, Lu C, Zheng G, He X, Wang M, Chen G, et al. Combination therapeutics in complex diseases. J Cell Mol Med. 2016;20:2231-40. https://doi.org/10.1111/jcmm.12930 PMid:27605177 DOI: https://doi.org/10.1111/jcmm.12930
Zhang SM, Zhu QG, Ding XX, Lin S, Zhao J, Guan L, et al. Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: A systematic review and meta-analysis. Cancer Manag Res. 2018;10:3393-404. https://doi.org/10.2147/CMAR. S167578 DOI: https://doi.org/10.2147/CMAR.S167578
Gadgeel SM, Ramalingam SS, Kalemkerian GP. Treatment of lung cancer. Radiol Clin North Am. 2012;50:961-74. https://doi.org/10.1016/j.rcl.2012.06.003 DOI: https://doi.org/10.1016/j.rcl.2012.06.003
Komite Nasional Penanganan Kanker (KPKN). Panduan Nasional Penanganan Kanker Paru. Kementrian Kesehatan Republik Indonesia Versi 1.0. Komite Nasional Penanganan Kanker; 2015.
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive methode for quantitave circulating tumor DNA with broad patients coverage. Nat Med. 2014;20(5):548-54. https://doi.org/10.1038/nm.3519 PMid:24705333 DOI: https://doi.org/10.1038/nm.3519
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16. https://doi.org/10.1016/j.gene.2005.10.018 PMid:16377102 DOI: https://doi.org/10.1016/j.gene.2005.10.018
Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013;31(8):1070-80. https://doi.org/10.1200/JCO.2012.43.3912 PMid:23401451 DOI: https://doi.org/10.1200/JCO.2012.43.3912
Perhimpunan Dokter Paru Indonesia (PDPI). Kanker Paru. Pedoman Diagnosis and Penatalaksanaan di Indonesia 2018. Jakarta: PT. Metro Offset Printing; 2018.
Schrank Z, Chhabra G, Lin L, Iderzorig T, Osude C, Khan N, et al. Current molecular-targeted therapies in NSCLC and their mechanism of resistance. Cancer. 2018;10:224. https://doi.org/10.3390/cancers10070224 PMid:29973561 DOI: https://doi.org/10.3390/cancers10070224
Rivero Del J, Enewold L, Thomas A. Metastatic lung cancer in the age of targeted therapy: Improving longterm survival. J Thorac Oncol. 2016;11:556-65. DOI: https://doi.org/10.21037/tlcr.2016.11.08
Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, Sheppard MN, et al. Small cell lung carcinoma (SCLC): A clinocophatologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26(9):1184-97. https://doi.org/10.1097/00000478-200209000-00009 PMid:12218575 DOI: https://doi.org/10.1097/00000478-200209000-00009
Soeroso NN, Zain-Hamid R, Sinaga BY, Sadewa AH, Syafiuddin T, Syahruddin E, et al. The role of CYP2A6 genetic polymorphism in nicotine dependence and tobacco consumption among bataknese male smokers. Open Access Maced J Med Sci. 2018;6(5):864-6. https://doi.org/10.3889/oamjms.2018.224 PMid:29875862 DOI: https://doi.org/10.3889/oamjms.2018.224
Soeroso NN, Tanjung MF, Afiani D, Pradana A, Tarigan SP, Wahyuni AS. Procalcitonin level in non-small cell lung cancer patients among indonesia population. Open Access Maced J Med Sci. 2018;6(11):2123-7. https://doi.org/10.3889.2018.421 PMid:30559873 DOI: https://doi.org/10.3889/oamjms.2018.421
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afitinib versus erlotinib as second line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-lung8): An open-label randomized controlled phase 3 trial. Lancet Oncol. 2015;16(8):897-907. https://doi.org/10.1016/S1470-2045(15)00006-6 PMid:26156651 DOI: https://doi.org/10.1016/S1470-2045(15)00006-6
Supriadi K. Angka Tahan Hidup Pasien Kanker Paru Kelompok Bukan Sel Kecil Nonskuamosa Yang Mendapat Terapi Target Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Dan Yang Mendapat Kemoterapi Lini Pertama Di Rumah Sakit Persahabatan. FK UI; 2014.
Sharma SV, Bell DW, Settlemen J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-81. https://doi.org/10.1038/nrc2088 PMid:17318210 DOI: https://doi.org/10.1038/nrc2088
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistic 2014. CA Cancer J Clin. 2014;64(1):9-29. https://doi.org/10.3322/caac.21208 PMid:24399786 DOI: https://doi.org/10.3322/caac.21208
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Desfrina Kasuma, Noni Novisari Soeroso, Setia Putra Tarigan, Elisna Syahruddin (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
